Morgan Stanley’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Morgan Stanley’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$298	Sell	28 -30	-52%	-$318	﹤0.01%	7786
2026 Q1	$608	Sell	58 -63	-52%	-$658	﹤0.01%	7591
2025 Q4	$1.25K	Buy	121 +89	+278%	+$919	﹤0.01%	7325
2025 Q3	$329	Sell	32 -77	-71%	-$790	﹤0.01%	7541
2025 Q2	$1.11K	Buy	109 +89	+445%	+$900	﹤0.01%	7325
2025 Q1	$200	Buy	+20	New	+$200	﹤0.01%	7473

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Morgan Stanley's DMAA Position: Q2 2026 in Review

Morgan Stanley reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 52% in Q2 2026, selling an estimated $318 and leaving 28 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #7786.

Morgan Stanley first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.25K in Q4 2025. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Morgan Stanley held 28 shares of Drugs Made In America Acquisition Corp worth $298 as of Q2 2026.
Morgan Stanley sold 30 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $318.
Drugs Made In America Acquisition Corp made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7786 holding.
Morgan Stanley first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
Morgan Stanley's Drugs Made In America Acquisition Corp position peaked at $1.25K in Q4 2025.
18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.